CRVO: Rasio kapitalisasi marang pendapatan CervoMed Corporation
Developing treatments for cognitive impairment entails immense risks and intense pressure from industry behemoths. The price/sales multiple of CervoMed Inc. (CRVO) confirms valuation volatility, with the current mark standing at 2542.40. CervoMed Inc. (CRVO) focuses on treating synaptic dysfunction, competing solely on the efficacy of its tests. The strategy of creating drugs for brain degeneration and the diversification of programs minimize dependence on a single project.
Rincian analitis perusahaan cervomed.com (CRVO)
- kuotasi saiki lan rata-rata prakiraan nilai:
- informasi kapitalisasi pasar:
- rincian valuasi buku bisnis:
- rincian struktur utang lan likuiditas bisnis:
Rasio Utang marang Ekuitas CervoMed Inc.|CRVO - Utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas CervoMed|CRVO - Gunggung utang perusahaan|Utang-utang marang aset resik CervoMed Corporation|CRVO - Utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan CervoMed|Rasio jangkoan perantara cervomed.com
- informasi bathi lan kelipatan valuasi:
CRVO - Penghasilan resik|Bathi sing dikarepake CervoMed Inc.|CRVO - Rasio rega marang bathi|Rasio prakiraan rega marang bathi CervoMed Corporation|CRVO - Rasio rega marang bathi tumrap wutah|Nilai perusahaan marang bathi operasional sadurunge panyusutan CervoMed Corporation|CRVO - Bathi operasional EBITDA|Bathi resik saben siji saham sajrone rolas wulan pungkasan CervoMed|CRVO - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan cervomed.com|CRVO - Wutah bathi saben saham ing taun lumaku|Dinamika bathi saben saham sing diarepake ing taun ngarep CervoMed Inc.
- rincian pendapatan lan dodolan emiten:
Ringkesan analitik perusahaan:CRVO, CervoMed
The P/S ratio determines the market value of one dollar of revenue, reflecting the premium investors place on the asset's current sales. This metric allows for an assessment of whether an issuer is overbought or undervalued relative to its operating income. By analyzing the median P/S, one can identify anomalies in a company's valuation. For CervoMed Inc. (CRVO), this indicator is critical, as a business model based on full R&D outsourcing makes revenue dependent on external contractors.
Perusahaan pesaing
BIIB (Biogen) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S NBIX (Neurocrine Corp)|Regencell Bioscience - Rasio rega marang pendapatan|Axsome Therapeutics - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan ACAD (ACADIA Pharmaceuticals)|Xenon (XENE) - Rasio rega marang pendapatan|Rega marang dodolan Viking Therapeutics Inc (VKTX)|SUPN (Supernus Pharma) - Multiplikator P/S|CPRX: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S DNLI|Koefisien rega marang pendapatan Harmony Biosciences|Biohaven Ltd - Kapitalisasi marang pendapatan|Multiplikator P/S Amylyx Pharmaceuticals, Inc. AMLX|TRVI: Kapitalisasi marang pendapatan|Koefisien rega marang pendapatan Praxis Corp PRAX|AVXL: Multiplikator P/S|CBLL (ceribell.com) - Rasio rega marang pendapatan|PRTA (Prothena Corporation) - Multiplikator P/S|Kapitalisasi marang pendapatan alector.com (ALEC)|Rasio rega marang pendapatan Annexon, Inc. (ANNX)|OMER - Rega marang dodolan|Multiplikator P/S NGNE (Neurogene Inc)|AC Immune (ACIU) - Rega marang dodolan|Voyager Therapeutics Inc - Multiplikator P/S|Neumora (NMRA) - Kapitalisasi marang pendapatan|SCLX: Multiplikator P/S|TVGN - Koefisien rega marang pendapatan|ACOG (Alpha Cognition Inc) - Multiplikator P/S|Kapitalisasi marang pendapatan cogrx.com (CGTX)|Rasio rega marang pendapatan Inhibikase Therapeutics Inc (IKT)|Koefisien rega marang pendapatan Cassava Sciences|Multiplikator P/S ASRT (Assertio Holdings)|COYA - Kapitalisasi marang pendapatan|vistagen.com - Multiplikator P/S|OVID: Rasio rega marang pendapatan|Acumen Pharmaceuticals, Inc (ABOS) - Rasio rega marang pendapatan|Rega marang dodolan Alterity Therapeutics Ltd (ATHE)|CLNN (Clene) - Multiplikator P/S|Rasio kapitalisasi marang pendapatan PEPG (PepGen)|Kapitalisasi marang pendapatan JUNS (Jupiter Neurosciences, Inc.)|Multiplikator P/S relmada.com (RLMD)|Rasio rega marang pendapatan Annovis Bio Corp ANVS|GRCE: Rasio kapitalisasi marang pendapatan|AIFF - Rasio rega marang pendapatan|KLTO (anewmeds.com) - Rasio kapitalisasi marang pendapatan|NRSN (NeuroSense Therapeutics Ltd.) - Kapitalisasi marang pendapatan|revivapharma.com - Rasio kapitalisasi pasar marang pendapatan|MTVA (metaviatx.com) - Multiplikator P/S|NRXS: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S HSDT|PASG - Rega marang dodolan|Multiplikator P/S NEUP (Neuphoria Therapeutics)|NERV: Rasio kapitalisasi marang pendapatan|ATHA: Kapitalisasi marang pendapatan|Addex Therapeutics Ltd - Kapitalisasi marang volume dodolan|Alzamend Neuro, Inc. (ALZN) - Rasio rega marang pendapatan|CYCN (Cyclerion Therapeutics Inc.) - Rasio rega marang pendapatan|Kapitalisasi marang pendapatan PTIX|KTTA: Rasio kapitalisasi pasar marang pendapatan|Kapitalisasi marang pendapatan CRGT (Cortigent Medical)|ATXI (Avenue Therapeutics, Inc.) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Brainstorm Cell Therapeutics, Inc. BCLI|Rasio kapitalisasi pasar marang pendapatan CARA|chromocell.com - Multiplikator P/S|Rasio rega marang dodolan ELYM|ITCI: Multiplikator P/S|Rega marang dodolan Longboard Pharmaceuticals, Inc. (LBPH)|Rasio rega marang pendapatan Marinus Pharmaceuticals, Inc.|NKGN: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S NRBO|SAGE: Rasio rega marang dodolan|Synaptogenix Inc. - Kapitalisasi marang pendapatan|Kapitalisasi marang volume dodolan TRVN (Trevena Inc.)|Vigil Neuroscience, Inc. - Multiplikator P/S|Anew Medical (WENA) - Kapitalisasi marang pendapatan|CERE (Cerevel Corp) - Kapitalisasi marang pendapatan
